MLN0415 is a novel, small molecule IKK2 inhibitor, discovered by Millennium scientists. In preclinical studies, MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of... Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.
- Mechanism
- Curator reviewed
MLN0415 is an oral, highly selective, small molecule inhibitor of IKK2, which targets a major inflammatory pathway. MLN0415 was shown to decrease NF-kB activation and down-regulate the expression of a number of inflammatory proteins. Because inflammatory proteins play a critical role in inflammation and drive the inflammatory response to disease, controlling these proteins may prevent or slow disease progression.
- Primary indication
- Investigated for use/treatment in inflammatory disorders (unspecified).Curator reviewed
- Code names
- MLN0415
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with MLN0415, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account